Program Overview

This is an exciting time in the treatment of cancer as a result of the tremendous volume of research being conducted worldwide. Our evolving understanding of the genomic and proteomic signaling responsible for aberrant cell growth has led to substantial improvement in our diagnostic and prognostic capability. Advances in imaging technology integrated with sophisticated software have enhanced both morphologic and biochemical visualization of tumors. New targets for therapeutic development are rapidly emerging in this post-genome era and the generation of new agents to be studied and applied in practice has accelerated. This program will provide attendees with the opportunity to participate in an interactive forum discussing novel technologies and therapies that look to impact future versions of the NCCN Guidelines

Last update 04/22/2008.